KYMR · Kymera Therapeutics, Inc.
$111.79
+1.28 (+1.16%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$9.31B
Shares
83.15M
Volume · Sep 30
1.02M
Avg daily vol (3M)
685.2K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$111.79
Open$110.74
Day$108.03–115.69
52W close$54.66–127.31
Avg vol 30d714K
Short int10.5M · 12.7% float · 16.1d
Short vol50%
Last earningsAug 5, 2026
DataAug 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$105.00M
Trailing 12 months
Net income (TTM)
−$299.60M
Trailing 12 months
Revenue growth YoY
+466.4%
Year over year
Operating margin
-333.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$124.48M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.0%
Year over year · more shares
Price change (1Y)
+88.9%
Trailing year
Short interest
12.7%
Latest settlement · 16.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Kymera completed enrollment in the KT-621 BROADEN2 Phase 2b AD trial about six months ahead of schedule, pulling forward topline data to year-end 2026 and planned Phase 3 initiation to mid-2027, while reporting $65M in Q2 collaboration revenue and reaffirming a cash runway into 2029.
Bullish
- + KT-621 BROADEN2 Phase 2b AD enrollment completed ~6 months early, pulling data readout forward to year-end 2026 and Phase 3 start to mid-2027
- + KT-579 (IRF5) Phase 1 healthy volunteer data expected 4Q26, with Phase 1b lupus POC study planned shortly after
- + Sanofi-initiated KT-485 Phase 1 triggered $20M milestone; Gilead exercised KT-200 option for $45M
- + Robust $1.5B cash position with runway into 2029, supporting Phase 2 completions and start of Phase 3 programs
Bearish
- − R&D expenses rose sharply year-over-year to $119.5M in Q2 2026
- − No additional collaboration revenue expected in 2026 after $65M already recognized, pressuring remaining-year revenue
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
−2%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
79%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+28%
trailing
YTD return
+44%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $115 › 200d $93 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$744.3K over 90 days · 100% sells
Short interest
Rising
12.66% of float · ▲ +1.5% MoM · 16.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
284 holders — near 3-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
−17%
Y/Y
EPS growth
−24%
Y/Y
Free cash flow
$-234.3M
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
79%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $115 › 200d $93 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$744.3K over 90 days · 100% sells
Short interest
Rising
12.66% of float · ▲ +1.5% MoM · 16.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
284 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $55
Now $112 · 79%
Range high $127
vs 200-day avg +20%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYMR
this stock
Kymera Therapeutics, Inc.
|
$9.31B | +43.7% | -16.7% | — | 12.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYMR | -3.2% | -6.1% | +28.0% | -5.9% | +43.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.5% | -6.2% | +15.8% | -5.3% | +31.8% |